Idiopathic Intracranial Hypertension (IIH)

1. Clinical Overview

Definition and Importance

Idiopathic Intracranial Hypertension (IIH) is a disorder characterized by elevated intracranial pressure (ICP) in the absence of an identifiable structural, vascular, or infectious cause. The condition predominantly affects obese women of childbearing age and poses a significant threat of permanent vision loss if untreated. [1,2]

The historical term "Benign Intracranial Hypertension" is obsolete and misleading because IIH carries a 10-25% risk of permanent visual impairment, including blindness. The primary clinical consequence is papilloedema leading to progressive optic nerve damage and irreversible visual field defects. [3]

Key Clinical Message

IIH is a neuro-ophthalmological emergency requiring urgent diagnosis and treatment to prevent blindness. The classic presentation comprises:

• Headache: Daily, positional, worse with Valsalva maneuvers
• Visual symptoms: Transient visual obscurations, blurred vision, diplopia
• Papilloedema: Bilateral optic disc swelling on fundoscopy
• Elevated CSF opening pressure: > 25 cmH2O on lumbar puncture [1,2]

Management centers on vision preservation through CSF pressure reduction. Weight loss is the only disease-modifying therapy with long-term efficacy. Acetazolamide provides symptomatic relief and modest visual benefit. Surgical interventions (venous sinus stenting, CSF shunting, optic nerve sheath fenestration) are reserved for medically refractory cases with threatened vision. [4,5]

---

2. Epidemiology

Incidence and Prevalence

The incidence of IIH is rising in parallel with the obesity epidemic. Between 1990 and 2017, the incidence increased by 350% in populations with high obesity rates. [6,7]

Risk Factors

Major risk factors (established):

• Obesity: BMI > 30 (RR 19 vs normal weight); strongest predictor [6]
• Female sex: 8:1 female-to-male ratio in adults [1]
• Childbearing age: Peak incidence 20-45 years [2]
• Recent weight gain: Rapid weight gain (> 5kg/6 months) [7]

Secondary causes (must exclude before diagnosing IIH):

• Medications: Tetracyclines (minocycline, doxycycline), retinoids (isotretinoin), vitamin A excess, lithium, corticosteroid withdrawal [8]
• Endocrine: Addison's disease, hypoparathyroidism, Cushing's syndrome (after treatment), PCOS [8]
• Hematological: Iron deficiency anemia, Factor V Leiden deficiency [9]
• Sleep disorders: Obstructive sleep apnea (independent association even after controlling for obesity) [10]

Special Populations

Paediatric IIH:

• Prepubertal children: Equal gender distribution, no obesity association [11]
• Postpubertal adolescents: Similar to adult pattern (female predominance, obesity) [11]

Male IIH:

• Represents less than 10% of cases; always warrants investigation for secondary causes [1]
• Higher risk of underlying pathology (OSA, medications, endocrine disorders) [12]

---

3. Aetiology and Pathophysiology

Pathophysiological Mechanisms

The exact etiology of IIH remains incompletely understood. Current evidence suggests a multifactorial model involving CSF dynamics, venous outflow obstruction, and metabolic factors. [13,14]

1. CSF Dynamics Impairment

Increased CSF production or decreased resorption:

• Arachnoid granulations fail to adequately drain CSF into venous sinuses [13]
• Obesity-related elevated abdominal pressure transmitted to central venous system increases baseline venous pressure, reducing CSF drainage gradient [14]
• Altered CSF composition (increased protein concentration) may impair arachnoid granulation function [13]

2. Venous Sinus Stenosis: Cause or Effect?

The "Chicken and Egg" Controversy:

Venous sinus stenosis (predominantly transverse sinus) is present in > 90% of IIH patients on MR venography. Two competing hypotheses exist: [15,16]

Hypothesis A - Stenosis as Effect (Secondary compression):

• Elevated ICP externally compresses the compliant venous sinus walls
• Evidence: LP-induced pressure reduction temporarily relieves stenosis on venography
• Stenosis location correlates with sites of arachnoid granulation concentration [15]

Hypothesis B - Stenosis as Cause (Primary obstruction):

• Stenosis creates venous outflow obstruction → venous hypertension → reduced CSF drainage → elevated ICP
• Evidence: Venous sinus stenting (relieving stenosis) normalizes ICP in 80-90% of patients
• Presence of pressure gradient across stenosis (> 8 mmHg) predicts stenting response [16,17]

Current Consensus: Likely a self-perpetuating cycle:

• Baseline stenosis (anatomical variant) → Mild venous outflow obstruction → Modest ICP elevation → External compression worsens stenosis → Further ICP elevation → Cycle continues [15,16]

3. Metabolic and Hormonal Factors

Adipose tissue dysfunction:

• Leptin resistance: IIH patients have elevated CSF leptin levels; leptin may directly increase CSF production [18]
• 11β-hydroxysteroid dehydrogenase type 1: Adipose tissue enzyme converting cortisone to cortisol; dysregulation linked to IIH pathogenesis [19]
• Adipokines: Altered adiponectin and resistin levels correlate with IIH severity [18]

Vitamin A metabolism:

• Elevated CSF retinol (vitamin A) levels found in IIH patients [20]
• Retinoids increase CSF production via choroid plexus effects [8]

Exam Detail: Molecular Mechanisms (Advanced):

Choroid Plexus Na-K-ATPase Activity:

• CSF production depends on active sodium transport by choroid plexus epithelial cells
• Carbonic anhydrase isoforms (II and IV) facilitate HCO3- transport coupled to sodium
• Acetazolamide inhibits carbonic anhydrase → reduced sodium-driven water flux → decreased CSF production by ~25-30% [21]

Aquaporin-1 (AQP1) Water Channels:

• Highly expressed in choroid plexus epithelium
• Mediates transcellular water movement following osmotic gradients
• Potential future therapeutic target (AQP1 inhibitors in development) [22]

Arachnoid Granulation Outflow Resistance:

• CSF drainage follows modified Starling's equation: CSF Flow = (ICP - Venous Pressure) / Outflow Resistance
• In IIH: Increased outflow resistance (granulation dysfunction) + elevated venous pressure = reduced CSF drainage
• Explains why even modest ICP elevation cannot be compensated [13]

---

4. Clinical Presentation

Symptoms

Headache (90-95% of patients) [1,2]

Characteristics:

• Daily or near-daily (85%); chronic pattern
• Quality: Pressure-like, dull, throbbing, or band-like
• Location: Often retro-orbital, frontal, or holocephalic
• Severity: Moderate to severe; impacts daily function

Exacerbating factors (pathognomonic features):

• Valsalva maneuvers: Coughing, sneezing, straining, bending forward
• Recumbency: Morning headache (ICP rises during sleep)
• Neck flexion: Jugular venous compression
• Physical exertion: Exercise, sexual activity [23]

Note: Headache characteristics do NOT correlate with ICP levels or visual prognosis. 10-15% of IIH patients are headache-free despite severe papilloedema. [23]

Visual Symptoms (60-75% of patients) [3]

1. Transient Visual Obscurations (TVOs) (60-70%):

   • Brief episodes (less than 30 seconds) of vision "greying out" or "blacking out"
   • Binocular or monocular
   • Triggered by postural changes (standing up, bending over)
   • Mechanism: Transient optic nerve head ischemia from intermittent CSF pressure spikes [3]
   • Clinical significance: Marker of threatened vision requiring urgent intervention

2. Blurred vision (50%):

   • Gradual onset over weeks to months
   • Due to papilloedema-induced hyperopia or progressive optic neuropathy
   • May fluctuate with CSF pressure variations

3. Photopsias (30%):

   • "Flashing lights" or "sparkles" in peripheral vision
   • Reflects retinal nerve fiber layer traction

4. Permanent visual loss (25% if untreated):

   • Progressive visual field constriction (peripheral > central)
   • Color vision deficits (red desaturation early sign)
   • Reduced visual acuity (late finding, indicates advanced damage) [3]

Other Symptoms

• Pulsatile tinnitus (60%): "Whooshing" sound synchronous with heartbeat; often unilateral; resolves with jugular compression (pathognomonic finding) [24]
• Diplopia (30%): Horizontal, worse on lateral gaze; due to sixth nerve palsy (see Signs) [1]
• Neck/shoulder pain (25%): Radicular pain from nerve root compression at skull base [25]
• Cognitive symptoms (20%): Memory difficulties, concentration impairment, "brain fog" [25]

Signs

1. Papilloedema (Bilateral in > 95%) [3]

Frisen grading scale (gold standard):

Associated fundoscopic findings:

• Splinter hemorrhages: Nerve fiber layer hemorrhages radiating from disc
• Cotton-wool spots: Retinal nerve fiber layer infarcts (ischemia)
• Paton's lines: Circumferential retinal folds radiating from disc (chronic IIH marker)
• Hard exudates: Lipid deposits (rare, suggests chronicity)
• Venous engorgement: Dilated retinal veins due to elevated ICP [3]

Chronic papilloedema (> 6 months):

• Disc pallor (optic atrophy): Pale, waxy disc color indicating irreversible axonal loss
• Optociliary shunt vessels: Retinochoroidal collaterals bypassing atrophic nerve
• "Champagne cork" appearance: Disc elevation with peripapillary atrophy [26]

2. Visual Field Defects [3]

Automated perimetry (Humphrey 24-2 or 30-2) findings:

Mean deviation (MD): Average visual field sensitivity loss compared to age-matched normals

• MD 0 to -5 dB: Mild loss
• MD -5 to -12 dB: Moderate loss (visual disability)
• MD < -12 dB: Severe loss (surgical intervention threshold) [3,27]

3. Sixth Nerve (Abducens) Palsy (20-30%) [1]

Presentation:

• Horizontal diplopia worse on lateral gaze (abduction failure)
• Unilateral (70%) or bilateral (30%)
• False localizing sign: Not indicative of posterior fossa pathology; caused by ICP-induced nerve stretching

Mechanism: Abducens nerve has longest intracranial course; tethered at Dorello's canal (petroclinoid ligament); susceptible to traction/stretching by downward brain displacement from elevated ICP [28]

4. Other Examination Findings

• Normal neurological examination: No focal deficits (key diagnostic criterion) [1]
• Obesity: BMI > 30 in 90% (measure and document) [6]
• Jugular compression test: Exacerbates pulsatile tinnitus; relieves after compression release [24]

---

5. Differential Diagnosis

Must-Not-Miss Diagnoses

1. Cerebral Venous Sinus Thrombosis (CVST) [29]

Why it mimics IIH:

• Venous outflow obstruction → elevated ICP → papilloedema + headache
• Similar demographics (young women on oral contraceptives)

Key distinguishing features:

• Acute/subacute onset (days to 2 weeks) vs gradual IIH onset (weeks to months)
• Severe headache: "Thunderclap" or rapidly progressive
• Focal neurology: Seizures (40%), hemiparesis, aphasia (absent in IIH)
• MR venography: Absent flow void in thrombosed sinus (vs narrowed but patent sinus in IIH)
• Imaging: Hemorrhagic venous infarcts on MRI (absent in IIH) [29]

Critical point: Always obtain MR venography (MRV) in suspected IIH to exclude CVST. MRI brain alone is insufficient.

2. Intracranial Mass Lesion (Tumor, Abscess, Cyst) [30]

Distinguishing features:

• Focal neurological signs: Hemiparesis, visual field defects (homonymous hemianopia), seizures
• MRI: Contrast-enhancing lesion, mass effect, edema
• Headache pattern: Progressive worsening, lateralizing pain
• Papilloedema: May be unilateral or asymmetric

3. Chronic Meningitis (TB, Cryptococcal, Sarcoid) [31]

Distinguishing features:

• Systemic features: Fever, night sweats, weight loss, immunosuppression
• CSF analysis: Elevated protein (> 1 g/L), lymphocytic pleocytosis, low glucose
• Imaging: Meningeal enhancement, hydrocephalus
• Cranial neuropathies: Multiple nerves affected (II, III, VI, VII)

Other Differential Diagnoses

---

6. Investigations

Essential Investigations

1. Neuroimaging: MRI Brain + MR Venography (MRV)

Indications: Mandatory in all suspected IIH cases before lumbar puncture [1,2]

MRI brain findings (1.5T or 3T preferred):

Normal findings (required for IIH diagnosis):

• Normal brain parenchyma (no mass, hydrocephalus, or structural lesion)
• No meningeal enhancement (excludes meningitis)

Supportive findings (suggestive of chronically elevated ICP):

*Stenosis is near-universal but also found in 10-20% of healthy controls; pressure gradient across stenosis (> 8 mmHg) is more specific. [15,16,34]

MR Venography (MRV) - Time-of-flight or Contrast-enhanced:

Purpose:

• Exclude cerebral venous sinus thrombosis (CVST) - absolute requirement
• Identify venous sinus stenosis location and severity
• Guide venous sinus stenting candidacy if medical therapy fails

Findings in IIH:

• Stenosis (typically bilateral transverse sinuses, right > left)
• Patent flow (distinguishes from thrombosis)
• Collateral venous drainage (via cortical veins, emissary veins) [15,16]

2. Lumbar Puncture with Opening Pressure Measurement

The Diagnostic Gold Standard Test [1,2]

Technique (critical for accuracy):

1. Patient positioning: Lateral decubitus (lying on side) with legs extended (NOT flexed - falsely elevates pressure)
2. Relaxation: Patient must be calm, breathing normally (Valsalva elevates pressure)
3. Manometer: Measure opening pressure before any CSF removal
4. Repeat measurement: Obtain closing pressure after removing 20-30 mL CSF

Diagnostic criteria:

Children (> 8 years): Threshold > 28 cmH2O (higher normal values) [11]

CSF analysis (required to exclude alternative diagnoses):

Therapeutic LP effect: Removing 20-30 mL CSF transiently reduces ICP by ~40%; symptom improvement confirms diagnosis but does NOT provide long-term benefit (pressure normalizes within 24-48h). [36]

3. Ophthalmological Assessment

Mandatory baseline and serial monitoring [3,27]

Components:

1. Visual acuity (Snellen chart):

   • Document for each eye
   • May be preserved until late-stage optic atrophy
   • less than 6/12 (20/40) warrants urgent surgical referral

2. Automated perimetry (Humphrey 24-2 or 30-2):

   • Baseline: Within 2 weeks of diagnosis
   • Follow-up: Monthly if untreated/unstable; 3-monthly once stable
   • Mean deviation (MD) and pattern standard deviation (PSD) tracked
   • Surgical threshold: MD worsening by > 2 dB or new scotomas despite medical therapy [27]

3. Fundoscopy (dilated pupils):

   • Document Frisen grade bilaterally
   • Photograph optic discs for comparison
   • Identify hemorrhages, pallor, optociliary shunts

4. Optical coherence tomography (OCT):

   • Quantifies retinal nerve fiber layer (RNFL) thickness
   • Peripapillary RNFL > 120 μm indicates active papilloedema
   • Progressive RNFL thinning (less than 75 μm) indicates irreversible atrophy
   • Advantage: Objective measurement for monitoring treatment response [37]

5. Color vision (Ishihara plates):

   • Red desaturation is early sign of optic neuropathy
   • less than 12/15 plates abnormal

Supportive Investigations

• Body mass index (BMI): Calculate and document (obesity is key risk factor; weight loss target)
• Blood pressure: Exclude malignant hypertension
• Full blood count: Exclude anemia (associated with IIH)
• Endocrine screen (if atypical features): TSH, morning cortisol, short Synacthen test (Addison's), testosterone (male IIH) [8]
• Sleep study (polysomnography): If OSA suspected (obesity, daytime somnolence, snoring) [10]

Investigations for Surgical Planning (if medical therapy fails)

Cerebral venography with manometry [16,17]:

• Gold standard to assess venous sinus stenosis hemodynamic significance
• Measures pressure gradient across stenosis (catheter-based)
• Gradient > 8 mmHg: Predicts good response to venous sinus stenting
• Gradient less than 4 mmHg: Stenosis not hemodynamically significant; stenting unlikely to help

---

7. Diagnostic Criteria

Modified Dandy Criteria (Friedman Criteria) [38]

Required for definite IIH diagnosis (all criteria must be met):

1. Papilloedema (bilateral; Frisen grade ≥2)

   • OR unilateral papilloedema with sixth nerve palsy

2. Normal neurological examination (except cranial nerve palsies: VI, rarely III, IV, VII)

   • No focal motor/sensory deficits
   • No cerebellar signs
   • No altered consciousness

3. Neuroimaging: Normal brain parenchyma (MRI preferred; CT acceptable if MRI contraindicated)

   • No hydrocephalus (ventricular size normal)
   • No mass lesion, abscess, or vascular malformation
   • No meningeal enhancement
   • MRV: No venous sinus thrombosis (patent flow confirmed)

4. Normal CSF composition:

   • Protein: Normal or low-normal
   • Glucose: Normal (> 60% plasma glucose)
   • Cell count: less than 5 WBC/μL (no pleocytosis)

5. Elevated CSF opening pressure:

   • Adults: ≥25 cmH2O (measured in lateral decubitus, legs extended, relaxed)
   • Children (> 8y): ≥28 cmH2O

IIH Without Papilloedema (IIHWOP) [35]:

A controversial diagnostic category; requires:

• All Modified Dandy criteria except papilloedema (no disc swelling on fundoscopy)
• PLUS at least one of:
  • Unilateral or bilateral sixth nerve palsy (without other cause)
  • Neuroimaging evidence of elevated ICP (empty sella, optic nerve sheath distension, posterior globe flattening)
  • MRV showing bilateral transverse sinus stenosis

Clinical utility: Explains patients with IIH symptoms (headache, tinnitus, sixth nerve palsy) but normal optic discs; represents ~5-10% of IIH cases. [35]

---

8. Classification and Grading

Papilloedema Severity (Frisen Scale) [39]

See Section 4: Signs for detailed grading table.

Visual Function Classification

---

9. Management

Management Algorithm

                     IIH DIAGNOSIS CONFIRMED
                              ↓
                 ┌────────────┴────────────┐
                 │   ASSESS VISUAL STATUS  │
                 └────────────┬────────────┘
                              ↓
         ┌────────────────────┼────────────────────┐
         │                    │                    │
    STABLE VISION      THREATENED VISION    FULMINANT IIH
    (Mild symptoms)    (Moderate deficits)  (Rapid progression)
         │                    │                    │
         ↓                    ↓                    ↓
  • Weight Loss          • High-Dose ACZ      • EMERGENCY
  • Acetazolamide        • Aggressive Weight     SURGERY
    500-1000mg BD          Loss                  (within 24-48h)
  • Headache mgmt        • Serial VF            
  • Monitor VF             (weekly)            Options:
    (3-monthly)          • Consider surgery    • CSF shunt
                           if worsening        • ONSF
                                               • VSS (if gradient)
                              ↓
                       Inadequate Response
                              ↓
                    ┌─────────┴─────────┐
                    │                   │
              Venous Sinus        No Stenosis/
               Stenosis           Gradient less than 8mmHg
              (Gradient > 8)             │
                    │                   ↓
                    ↓              CSF Diversion:
            Venous Sinus        • VP/LP Shunt
              Stenting          • ONSF (vision only)

Medical Management

1. Weight Loss (The Only Curative Treatment) [40,41]

Evidence:

• 6-10% body weight reduction induces sustained ICP normalization in 65-75% of patients [40]
• Bariatric surgery (gastric sleeve, bypass): 94% achieve complete remission; sustained long-term [42]
• GLP-1 receptor agonists (semaglutide, liraglutide): Mean weight loss 12-15%; favorable headache and papilloedema outcomes [43]

Mechanism: Weight loss reduces abdominal/thoracic pressure → lowers central venous pressure → improves CSF drainage gradient → normalizes ICP [40]

Implementation:

Target: ≥10% body weight reduction; sustained (not rapid crash dieting) [40]

Monitoring: Weigh monthly; adjust therapy if less than 0.5kg/week loss over 3 months

2. Acetazolamide (Diamox) [4]

Mechanism: Carbonic anhydrase inhibitor → reduces CSF production at choroid plexus by ~25-30% → lowers ICP [21]

Evidence: IIH Treatment Trial (IIHTT) - RCT of 165 patients [4]:

• Acetazolamide + diet vs placebo + diet: Modest visual field improvement (+1.43 dB MD vs +0.71 dB; p=0.049)
• Weight loss was primary driver of benefit (greater effect than acetazolamide alone)
• Conclusion: Acetazolamide provides modest symptomatic benefit for mild-moderate IIH; NOT sufficient for severe visual loss

Dosing:

Adverse effects (dose-dependent; often limit therapy):

Contraindications:

• Pregnancy (1st and 3rd trimesters): Teratogenic in animal models; avoid unless vision-threatening IIH [44]
• Sulfonamide allergy: Cross-reactivity (acetazolamide is sulfonamide derivative)
• Severe renal impairment (eGFR less than 30): Reduced efficacy; increased toxicity
• Severe hepatic impairment: Hepatic encephalopathy risk

Monitoring:

• Baseline: FBC, U&E, bicarbonate, LFTs
• Follow-up: U&E and bicarbonate at 2 weeks, then 3-monthly

3. Topiramate (Alternative to Acetazolamide) [45]

Mechanism: Weak carbonic anhydrase inhibitor + GABA agonist; additional benefits:

• Weight loss: 5-10% body weight reduction (appetite suppression)
• Migraine prophylaxis: Reduces headache frequency (independent of ICP effect)

Dosing:

• Start 25mg OD (at night)
• Titrate by 25mg/week to 100-200mg/day (divided BD)
• Maximum 400mg/day

Advantages over acetazolamide:

• Dual benefit: ICP reduction + weight loss + headache prophylaxis
• Better tolerated in sulfa allergy patients (minimal cross-reactivity)

Disadvantages:

• Cognitive side effects: "Topiramate stupor"
• word-finding difficulty, memory impairment, concentration problems (20-30%) [45]
• Psychiatric effects: Depression, anxiety (monitor closely)
• Teratogenicity: Category D (higher risk than acetazolamide); contraindicated in pregnancy
• Kidney stones: Similar risk to acetazolamide

Clinical role: Consider in patients intolerant of acetazolamide or requiring concomitant migraine prophylaxis

4. Furosemide (Loop Diuretic) [46]

Evidence: Weak; limited RCT data; not recommended as monotherapy

Mechanism: Reduces CSF production via choroid plexus sodium transport inhibition (less effective than carbonic anhydrase inhibitors)

Dosing: 40-80mg OD

Clinical role: Adjunct to acetazolamide in refractory cases; NOT first-line

Adverse effects: Hypokalemia, hyponatremia, dehydration, ototoxicity (high doses)

5. Headache Management [23]

Important principle: Headache in IIH may persist despite papilloedema resolution and ICP normalization (occurs in 40-50% post-treatment). This represents a chronic migraine phenotype independent of ICP. [23]

Approach:

1. Optimize ICP-lowering therapy: Acetazolamide titration, weight loss
2. If headache persists despite ICP control:
   • Migraine prophylaxis: Topiramate 50-100mg BD, propranolol 40-80mg BD, amitriptyline 25-75mg nocte
   • Acute treatment: Triptans (sumatriptan 50-100mg PRN) if migraine phenotype
   • Avoid opioids: Risk of medication-overuse headache; chronic use
3. Reassess ICP: Repeat LP if clinical deterioration (headache worsening may indicate ICP relapse)

Surgical Management

Indications:

1. Fulminant IIH: Rapid visual deterioration (> 2 dB MD decline/week) despite maximum medical therapy
2. Severe visual loss at presentation: VA less than 6/18 (20/60) or MD < -12 dB
3. Progressive visual deterioration on serial perimetry despite medical therapy
4. Intolerable headache refractory to medical management (quality-of-life indication; NOT for vision-threatening disease alone)
5. Medication intolerance: Unable to tolerate acetazolamide/topiramate due to side effects

1. Venous Sinus Stenting (VSS) [16,17,47]

Concept: Endovascular stent placement across transverse sinus stenosis to relieve venous outflow obstruction → reduce ICP

Patient selection (strict criteria):

• Documented stenosis on MRV (typically bilateral transverse sinuses)
• Hemodynamically significant gradient: Pressure gradient > 8 mmHg across stenosis on catheter venography [16,17]
• Failed medical therapy: ≥3 months maximum-dose acetazolamide + weight loss attempt
• No contraindication to antiplatelet therapy: Dual antiplatelets required post-stent

Procedure:

1. Transfemoral venous access
2. Catheter venography with manometry (measure gradient)
3. Self-expanding stent deployment (6-10mm diameter) across stenosis
4. Post-deployment venography confirms stenosis relief

Outcomes (meta-analysis of 399 patients [47]):

Complications:

Advantages:

• Minimally invasive: No craniotomy; same-day discharge often possible
• Treats both headache and vision: Unlike ONSF (vision only)
• Lower revision rate than CSF shunts (10% vs 50% at 2 years) [48]
• Immediate tinnitus relief: Most dramatic symptomatic benefit

Disadvantages:

• Requires antiplatelet therapy: Bleeding risk; contraindicated if bleeding disorder
• Not all patients suitable: 20% lack significant gradient; stenting ineffective
• Specialized procedure: Requires interventional neuroradiology expertise; not universally available

2. Cerebrospinal Fluid Diversion (CSF Shunting) [49]

Types:

A. Lumboperitoneal (LP) Shunt:

• Mechanism: Silicone catheter from lumbar thecal sac to peritoneal cavity; CSF drains down pressure gradient
• Advantages: No craniotomy; simpler procedure
• Disadvantages:
  • "High failure rate: 50% require revision within 2 years (catheter migration, obstruction)"
  • "Low-pressure headache: Over-drainage common (50%) [49]"
  • "Radicular pain: Nerve root irritation from catheter"
  • "Not suitable for obesity: Abdominal fat impairs catheter placement/function"

B. Ventriculoperitoneal (VP) Shunt:

• Mechanism: Silicone catheter from lateral ventricle to peritoneal cavity; CSF drains continuously
• Advantages: More reliable CSF diversion; established neurosurgical procedure
• Disadvantages:
  • Small ventricles in IIH: "Slit ventricle syndrome"
• difficult catheter placement; high failure rate
  • "Craniotomy required: Burr hole; increased operative risk"
  • "Shunt failure: 50% need revision within 2 years (obstruction, infection, over-drainage) [49]"
  • "Subdural hematoma: Over-drainage → intracranial hypotension → subdural collection (10%)"

Outcomes:

Complications:

Clinical role:

• Second-line to venous sinus stenting (if gradient present)
• First-line if VSS contraindicated (bleeding disorder) or no stenosis/gradient
• Vision-threatening IIH requiring urgent ICP reduction (within 24-48h) when VSS not immediately available

3. Optic Nerve Sheath Fenestration (ONSF) [50]

Concept: Surgical slits in optic nerve sheath → CSF drainage from perioptic subarachnoid space → decompress optic nerve → prevent further visual loss

Procedure:

• Approach: Medial transconjunctival or lateral orbitotomy
• Technique: Multiple small incisions (fenestrations) in optic nerve dural sheath 3-5mm posterior to globe
• Mechanism: CSF "leaks" through fenestrations into orbital tissues; local effect only (does NOT reduce global ICP)

Outcomes:

Complications:

Advantages:

• Vision-specific: Highest success rate for preventing visual loss
• No systemic complications: Unlike shunts (no infection, obstruction)
• Unilateral procedure: Can perform on worse eye first

Disadvantages:

• Does NOT treat headache: ICP remains elevated
• Does NOT prevent disease progression: Fenestrations may close; contralateral eye at risk
• High surgical skill requirement: Specialized oculoplastic/neuro-ophthalmology surgery

Clinical role:

• Asymmetric papilloedema: Severe visual loss one eye; preserve that eye
• Unilateral vision threat: Patient refuses shunt/stenting but needs vision protection
• Rapidly failing vision in patient with contraindications to VSS/shunt (e.g., anticoagulation for other indication)

Comparative Surgical Outcomes Summary

---

10. Special Populations

Pregnancy and IIH [44,51]

Key Principles:

• IIH may worsen, improve, or remain stable during pregnancy (unpredictable) [44]
• Vision-threatening IIH is indication for treatment despite pregnancy
• Non-vision-threatening IIH: Avoid medications; monitor closely

Management approach:

1st Trimester:

• Avoid all medications if vision stable (teratogenicity risk)
• If vision-threatening:
  • Serial LP (therapeutic CSF removal every 2-4 weeks) - safest option [51]
  • Acetazolamide if absolutely necessary (Category C; risk-benefit discussion)
  • Consider pregnancy termination if fulminant IIH (rare)

2nd/3rd Trimester:

• Acetazolamide relatively safer (organogenesis complete); use if vision deteriorating
• Serial LPs preferred to medications if feasible
• Delivery planning:
  • "Mode of delivery: Vaginal delivery safe (Valsalva during pushing does NOT worsen outcome) [51]"
  • Cesarean section if obstetric indications only (NOT for IIH)
  • Regional anesthesia (epidural/spinal) safe

Postpartum:

• Monitor closely: Disease may flare postpartum (hormonal shifts)
• Breastfeeding: Acetazolamide enters breast milk (avoid if possible; use if vision-threatening)
• Contraception: Avoid estrogen-containing contraceptives (theoretical IIH risk); progesterone-only safe

Paediatric IIH [11]

Distinct features:

• Prepubertal children: No gender predominance; obesity NOT associated
• Adolescents: Adult pattern (female, obese)
• Presentation: Headache less common; behavioral changes (irritability, poor school performance)

Diagnosis:

• Higher LP opening pressure threshold: > 28 cmH2O (children > 8y) [11]
• Sedation often required for LP; consider general anesthesia

Management:

• Weight loss if obese
• Acetazolamide 15-25 mg/kg/day (divided doses)
• Better prognosis than adults: 70% resolve spontaneously [11]

---

11. Prognosis and Long-Term Outcomes

Visual Prognosis [3,27]

Predictors of poor visual outcome [3,27]:

• Severe papilloedema at presentation (Frisen grade ≥4)
• Baseline MD < -8 dB
• Delayed diagnosis (> 6 months symptom duration)
• Male gender (worse prognosis, unclear mechanism) [12]
• Poor treatment adherence (missed follow-up, medication non-compliance)
• African-Caribbean ethnicity (higher risk severe visual loss) [52]

Headache Prognosis [23]

• 40-50% have persistent headache despite papilloedema resolution
• Headache character changes to chronic migraine phenotype (ICP-independent)
• Requires separate headache management (migraine prophylaxis)

Recurrence Risk [53]

Prevention:

• Sustained weight loss: Single most important factor
• Lifelong weight monitoring: Regain > 5kg warrants clinical review
• Avoid IIH-triggering medications: Tetracyclines, retinoids, vitamin A

---

12. Key Guidelines and Evidence

Major Guidelines

1. UK Consensus Guidelines (Mollan et al., 2018) [1]:

   • J Neurol Neurosurg Psychiatry 2018;89:1088-1100
   • First international consensus on IIH management
   • Recommends MRI+MRV, LP, serial perimetry, weight loss as first-line
   • Defines surgical thresholds

2. American Academy of Neurology Quality Measures (2019):

   • Mandates visual field testing at diagnosis and 3-monthly intervals
   • Requires documented weight loss counseling
   • Recommends OCT for objective monitoring

Landmark Trials

1. IIH Treatment Trial (IIHTT), 2014 [4]:

   • RCT: Acetazolamide (up to 4g/day) + low-sodium diet vs placebo + diet
   • N=165 patients; mild visual loss (MD -2 to -7 dB)
   • Result: Modest visual field improvement with acetazolamide (+1.43 dB vs +0.71 dB; p=0.049)
   • Conclusion: Acetazolamide beneficial for mild IIH; weight loss more important

2. Venous Sinus Stenting Meta-Analysis (Azzam et al., 2024) [47]:

   • Pooled data: 399 patients across 25 studies
   • Result: 88% papilloedema resolution, 83% headache improvement, 12% restenosis rate
   • Conclusion: VSS highly effective; comparable outcomes to shunting with lower revision rate

---

13. Examination Focus

Viva Voce Scenarios

Viva Point: Opening Statement (Consultant asks: "Tell me about Idiopathic Intracranial Hypertension"):

"Idiopathic Intracranial Hypertension is a disorder of elevated intracranial pressure in the absence of structural, vascular, or infectious causes. It predominantly affects obese women of childbearing age and is characterized by papilloedema, headache, and visual symptoms. The primary clinical concern is permanent vision loss, occurring in 10-25% if untreated. Diagnosis requires fulfilling the Modified Dandy criteria, including papilloedema, normal MRI brain and MR venography excluding sinus thrombosis, normal CSF composition, and elevated opening pressure > 25 cmH2O. Management focuses on vision preservation through weight loss, acetazolamide, and surgical intervention if medical therapy fails."

Common Exam Questions

1. What are the Modified Dandy diagnostic criteria for IIH?

Five criteria must ALL be met:

1. Papilloedema (bilateral) on fundoscopy
2. Normal neurological examination (except cranial nerve palsies: VI, rarely III/IV/VII)
3. Normal neuroimaging: MRI brain (no mass, no hydrocephalus) + MR venography (no thrombosis)
4. Normal CSF composition: Protein, glucose, cell count within normal limits
5. Elevated CSF pressure: Opening pressure ≥25 cmH2O (adults) or ≥28 cmH2O (children), measured in lateral decubitus position with legs extended

Critical addition: MRV is mandatory to exclude cerebral venous sinus thrombosis, which perfectly mimics IIH. [1,38]

2. Why is the Vth cranial nerve palsy a "false localizing sign" in IIH?

The abducens (sixth) nerve has the longest intracranial course of all cranial nerves, traveling from the pontomedullary junction through the subarachnoid space, over the petrous apex, and through Dorello's canal (beneath the petroclinoid ligament) before entering the cavernous sinus. It is tethered at Dorello's canal, making it susceptible to stretching when the brain is displaced downward by elevated ICP. This produces a unilateral or bilateral sixth nerve palsy (horizontal diplopia, failure of abduction) without indicating a posterior fossa lesion - hence a "false localizing" sign. [28]

3. What is the mechanism of action of acetazolamide?

Acetazolamide is a carbonic anhydrase inhibitor. In the choroid plexus epithelium, CSF production depends on active sodium transport coupled to bicarbonate (HCO3-) via carbonic anhydrase enzymes (isoforms II and IV). The enzyme catalyzes the reaction:

CO2 + H2O ↔ H2CO3 ↔ H+ + HCO3-

Bicarbonate is co-transported with sodium into the CSF; water follows osmotically. By inhibiting carbonic anhydrase, acetazolamide reduces HCO3- generation → reduced sodium transport → decreased water flux → 25-30% reduction in CSF production → lower ICP. [21]

4. What investigations would you request in a 25-year-old obese woman presenting with headache and papilloedema?

Immediate/urgent investigations:

1. MRI brain + MR venography (MRV):

   • Exclude mass lesion, hydrocephalus (MRI brain)
   • Exclude cerebral venous sinus thrombosis (MRV) - mandatory; single most important differential
   • Identify supportive IIH features (empty sella, posterior globe flattening, optic nerve sheath distension)

2. Lumbar puncture with opening pressure:

   • Measure opening pressure (lateral decubitus, legs extended, relaxed)
   • CSF analysis: Exclude meningitis/SAH (protein, glucose, cell count, microscopy/culture)
   • Diagnostic threshold: ≥25 cmH2O

3. Ophthalmology assessment (same day or within 48h):

   • Visual acuity (Snellen)
   • Automated perimetry (Humphrey 24-2): Baseline visual fields
   • Dilated fundoscopy: Grade papilloedema (Frisen scale), photograph discs
   • OCT: Quantify retinal nerve fiber layer thickness

Supportive investigations:

• BMI calculation (document obesity)
• Blood pressure (exclude malignant hypertension)
• FBC (exclude anemia)
• Pregnancy test (if reproductive age)
• Medication review (tetracyclines, retinoids, vitamin A)

Rationale: MRV is critical to exclude CVST (presents identically to IIH); LP confirms elevated pressure; ophthalmology establishes baseline visual function for monitoring treatment response. [1,2]

5. How would you manage a patient with IIH and progressive visual field loss despite maximum-dose acetazolamide?

This represents medically refractory, vision-threatening IIH - a neurosurgical/interventional emergency. Management steps:

1. Urgent ophthalmology review (within 24-48h):

   • Repeat visual fields to quantify progression (MD decline rate)
   • If MD worsening > 2 dB or new scotomas → immediate surgical referral

2. Catheter cerebral venography with manometry:

   • Assess venous sinus stenosis hemodynamic significance
   • Measure pressure gradient across stenosis
   • If gradient > 8 mmHg → venous sinus stenting (first-line surgical option) [16,17]

3. Surgical intervention (within 48-72h):

   • Venous sinus stenting if gradient > 8 mmHg: 90% vision improvement; 83% headache improvement; low revision rate [47]
   • CSF shunt (VP or LP) if no gradient or VSS contraindicated: Reliable ICP reduction but 50% revision rate at 2 years [49]
   • Optic nerve sheath fenestration if isolated vision threat without headache: 85-90% vision stabilization but does NOT treat ICP [50]

4. Optimize medical therapy during surgical planning:

   • Continue maximum-dose acetazolamide (4g/day)
   • Aggressive weight loss (dietitian referral, consider GLP-1 agonists if time permits)
   • Consider repeat therapeutic LP (remove 20-30 mL CSF) for temporary pressure relief

Key point: Do NOT delay surgery if progressive visual loss documented. Permanent optic nerve damage occurs rapidly; delayed intervention may be too late. [1,27]

Clinical Pearls

"The Whooshing Sound": Pulsatile tinnitus (hearing one's heartbeat) is a highly specific symptom for raised ICP. It often stops if the patient compresses their jugular vein (Queckenstedt's sign equivalent), confirming venous etiology.

"Transient Visual Obscurations (TVOs)": Brief (less than 30 sec) episodes of vision "greying out," triggered by bending over or standing up, indicate optic nerve head ischemia from intermittent CSF pressure spikes. TVOs are a red flag for threatened vision requiring urgent treatment escalation.

"The Empty Sella": A common MRI finding in IIH (70% prevalence). Chronic elevated ICP causes CSF pulsations to flatten the pituitary gland against the floor of the sella turcica. While suggestive of IIH, it also occurs in 10-15% of healthy individuals (normal variant).

"Don't Miss the Thrombus": Cerebral venous sinus thrombosis (CVST) mimics IIH perfectly - young woman, headache, papilloedema, elevated CSF pressure. You MUST request an MR venogram (MRV), not just MRI brain. MRV shows absent flow in thrombosed sinus (vs patent but narrowed sinus in IIH).

"The Sixth Nerve Paradox": A unilateral or bilateral sixth nerve palsy in IIH does NOT indicate a brainstem lesion (despite the nerve nucleus being in the pons). It is a "false localizing sign" caused by nerve stretching from elevated ICP. Do NOT panic and order unnecessary brainstem imaging.

Common Mistakes

❌ Diagnosing IIH without MRV:

• Error: Obtaining only MRI brain; missing CVST
• Consequence: Life-threatening CVST untreated (requires anticoagulation, not acetazolamide)
• Correction: Always request MRI + MRV in suspected IIH [29]

❌ Delaying surgery in progressive visual loss:

• Error: "Let's try increasing acetazolamide to 4g and see in 3 months"
• Consequence: Irreversible optic atrophy; permanent blindness
• Correction: Progressive visual field loss (MD decline > 2 dB or new scotomas) = surgical emergency (VSS/shunt/ONSF within 48-72h) [1,27]

❌ Measuring LP opening pressure in seated position:

• Error: Sitting position falsely elevates pressure due to hydrostatic column
• Consequence: False-positive diagnosis
• Correction: Lateral decubitus position with legs extended (NOT flexed) and patient relaxed [38]

❌ Treating headache instead of vision:

• Error: Focusing on headache control while neglecting visual field monitoring
• Consequence: Silent progressive visual loss (patients adapt to peripheral field constriction; may not notice until severe)
• Correction: Serial perimetry (monthly if untreated, 3-monthly once stable) is mandatory; headache is secondary consideration [1,3]

❌ Stopping acetazolamide due to paresthesias:

• Error: "Patient can't tolerate tingling in fingers/toes; stopping medication"
• Consequence: ICP rebound; papilloedema worsens
• Correction: Paresthesias are common (80%) and benign; educate patient; gradual dose escalation improves tolerance; potassium supplementation does NOT help (common misconception) [4]

---

14. Patient/Layperson Explanation

What is Idiopathic Intracranial Hypertension?

Idiopathic Intracranial Hypertension (IIH) is a condition where the fluid pressure around your brain and spinal cord becomes too high. The fluid is called cerebrospinal fluid (CSF), and it normally acts as a cushion to protect your brain. In IIH, there is too much pressure from this fluid, which can damage the nerves that connect your eyes to your brain (the optic nerves), potentially causing permanent vision loss.

The word "idiopathic" means we don't know exactly why it happens, though it is strongly linked to being overweight.

Why me?

IIH almost always affects women of childbearing age (20-45 years) who are overweight or obese. About 90 out of every 100 people with IIH are women, and most have a body mass index (BMI) over 30.

We don't fully understand why obesity causes IIH, but it likely has to do with how extra body weight increases pressure inside your abdomen and chest, which then affects the pressure around your brain.

Is it dangerous?

IIH is not life-threatening, but it can cause permanent blindness if left untreated. This is why it's sometimes called "pseudotumor cerebri" (false brain tumor) - it mimics the symptoms of a brain tumor (headaches, vision problems) but there is no tumor.

The main risks are:

• Vision loss: 10-25% of people with IIH develop permanent vision problems, ranging from mild blind spots to complete blindness
• Chronic headaches: Headaches may persist even after treatment

What are the symptoms?

Common symptoms include:

• Headaches: Daily headaches, often worse when lying down, coughing, or bending over
• Vision problems: Blurred vision, brief episodes of vision "blacking out" (lasting seconds), or seeing flashing lights
• Whooshing sound in your ear: Hearing your heartbeat as a "whooshing" noise (pulsatile tinnitus)
• Double vision: Seeing two images of the same object (diplopia)

How is it diagnosed?

Your doctor will perform several tests:

1. MRI scan of your brain: To rule out other causes like a tumor or blood clot
2. Lumbar puncture (spinal tap): A needle inserted into your lower back to measure the pressure of the fluid around your spinal cord. If the pressure is too high (above 25 cmH2O), it confirms the diagnosis
3. Eye examination: An ophthalmologist (eye specialist) will look at the back of your eyes to check for swelling of the optic nerves (papilloedema) and test your peripheral vision

What is the treatment?

The most effective treatment is weight loss. Losing just 5-10% of your body weight (for example, 5-10 kg if you weigh 100 kg) can significantly lower the pressure around your brain and often leads to complete resolution of symptoms.

Other treatments include:

• Acetazolamide (Diamox): A water tablet that reduces the amount of fluid produced around your brain. It can cause side effects like tingling in your fingers and toes, tiredness, and a metallic taste
• Regular eye tests: To monitor your vision and ensure it's not getting worse
• Surgery: If weight loss and medications don't work, or if your vision is getting rapidly worse, surgery may be needed. Options include:
  • "Venous sinus stenting: A small tube (stent) placed in a vein in your brain to improve drainage"
  • "Shunt: A tube placed to drain excess fluid from around your brain to your abdomen"
  • "Optic nerve sheath fenestration: A procedure to relieve pressure directly on the optic nerve"

Will I get better?

With treatment, most people (60-70%) have significant improvement in their symptoms, and vision loss can be prevented. However, headaches may persist even after the pressure around your brain returns to normal.

The condition can come back if you regain weight, so maintaining a healthy weight long-term is very important.

What should I do now?

1. Attend all your eye appointments: Regular vision tests are essential to catch any worsening early
2. Take your medications as prescribed: Even if you experience side effects like tingling (this is normal and not dangerous)
3. Focus on weight loss: This is the single most important thing you can do to control your condition
4. Avoid certain medications: Tetracycline antibiotics (like doxycycline), vitamin A supplements, and acne treatments (like isotretinoin) can worsen IIH
5. Report new symptoms immediately: If you notice sudden worsening of vision, new blind spots, or severe headaches, contact your doctor urgently

---

15. References

1. Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100. doi:10.1136/jnnp-2017-317440

2. Wakerley BR, Tan MH, Ting EY. Idiopathic intracranial hypertension. Cephalalgia. 2015;35(3):248-261. doi:10.1177/0333102414534329

3. Xie JS, Donaldson L, Margolin E. Papilledema: A review of etiology, pathophysiology, diagnosis, and management. Surv Ophthalmol. 2022;67(4):1135-1159. doi:10.1016/j.survophthal.2021.11.007

4. Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641-1651. doi:10.1001/jama.2014.3312

5. Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management. J Clin Neurosci. 2022;95:172-179. doi:10.1016/j.jocn.2021.11.029

6. Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016;15(1):78-91. doi:10.1016/S1474-4422(15)00298-7

7. Subramaniam S, Fletcher WA. Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review. J Neuroophthalmol. 2017;37(2):197-205. doi:10.1097/WNO.0000000000000448

8. Friedman DI. Special Considerations in the Treatment of Idiopathic Intracranial Hypertension. Curr Neurol Neurosci Rep. 2024;25(1):8. doi:10.1007/s11910-024-01398-z

9. Yiangou A, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms. Nat Rev Neurol. 2023;19(12):769-785. doi:10.1038/s41582-023-00893-0

10. Anderson M, Baird-Daniel E, Meyer RM, Levitt MR. Idiopathic Intracranial Hypertension. Neurosurg Clin N Am. 2024;35(3):287-291. doi:10.1016/j.nec.2024.02.001

11. Gaier ED, Heidary G. Pediatric Idiopathic Intracranial Hypertension. Semin Neurol. 2019;39(6):704-710. doi:10.1055/s-0039-1698743

12. Rohit W, Rajesh A, Mridula R, Jabeen SA. Idiopathic Intracranial Hypertension - Challenges and Pearls. Neurol India. 2021;69(Supplement):S434-S442. doi:10.4103/0028-3886.332276

13. Fargen KM, Coffman S, Torosian T, et al. "Idiopathic" intracranial hypertension: An update from neurointerventional research for clinicians. Cephalalgia. 2023;43(4):3331024231161323. doi:10.1177/03331024231161323

14. Leishangthem L, SirDeshpande P, Dua D, Satti SR. Dural venous sinus stenting for idiopathic intracranial hypertension: An updated review. J Neuroradiol. 2019;46(2):148-154. doi:10.1016/j.neurad.2018.09.001

15. Nicholson P, Brinjikji W, Radovanovic I, et al. Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerv Surg. 2019;11(4):380-385. doi:10.1136/neurintsurg-2018-014172

16. Papadimitriou K, Werner C, White TG, et al. Occipital venous sinus stenting for idiopathic intracranial hypertension and pulsatile tinnitus: A case series. Interv Neuroradiol. 2024 May 7:15910199241245451. doi:10.1177/15910199241245451

17. Ong F, Phillips T, Selkirk G, McAuliffe W. Intracranial venous stenting for idiopathic intracranial hypertension. J Med Imaging Radiat Oncol. 2023;67(5):526-530. doi:10.1111/1754-9485.13505

18. Krajnc N, Itariu B, Macher S, et al. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023;24(1):89. doi:10.1186/s10194-023-01631-z

19. Sinclair AJ, Woolley R, Mollan SP. Idiopathic intracranial hypertension. JAMA. 2014;312(10):1059-1060. doi:10.1001/jama.2014.8894

20. Thurtell MJ. Idiopathic Intracranial Hypertension. Continuum (Minneap Minn). 2019;25(5):1289-1309. doi:10.1212/CON.0000000000000770

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow institutional protocols.